Generics drugmaker Mylan NV (MYL.O), which is in the middle of a three-way takeover battle, has said it is unwilling to sell itself to Israeli rival Teva Pharmaceuticals Industries Ltd (TEVA.TA), but would consider buying that company down the road, Mylan Executive Chairman Robert Coury told investors this week. The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter drugmaker Perrigo Co Plc (PRGO.N)…
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
By Olivia Oran and Caryoline Humer
Teva Pharmaceutical Industries Ltd. is in discussions with banks to raise about $25 billion in financing to back its unsolicited bid for Mylan NV, according to people with knowledge of the matter… [READ MORE]
By Dinesh Nair Manuel Baigorri Ed Hammond